Amanda C Peltier, MD
Disclosures: Consulting Fee-patisiran-Alnylam Pharmaceutical-Likely-Inherited TTR amyloidosis-Option_2-Option_2-1. Consulting on research projects 2. PI of expanded access program 3. in contract for future study.|Consulting Fee-Hizentra-CSL Beringer-None-CIDP-Option_2-Option_2-consulting on research, have pending investigator initiated research project application with this company.|Consulting Fee-Have consulted with company on product and education on primary disease-Akcea-will be discussed-hereditary ATTR amyloidosis-Option_2-Option_2-education on primary disease, hereditary amyloidosis for employees.
No Bio Available.